Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible?: A randomized multicenter pilot trial

K P Nguyen; G J Knuiman; W A M Blokx; L Hoogedoorn; T Smits; M J P Gerritsen

doi:10.1080/09546634.2018.1484558

Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial

K P Nguyen
, G J Knuiman
, W A M Blokx
, L Hoogedoorn
, T Smits
, M J P Gerritsen

Research output: Contribution to journal › Article › Academic › peer-review

2 Downloads (Pure)

Abstract

BACKGROUND: Topical methyl aminolevulinate photodynamic therapy (MAL-PDT) is highly effective for the treatment of superficial basal cell carcinoma (sBCC). Current European treatment protocol requires two hospital visits, which is costly and unpractical. The aim of this study was to evaluate the efficacy of fractionated MAL-PDT, using two light fractions at 3 and 4 h compared to illumination at 3 and 5 h after MAL-application.

METHODS: Thirty patients were randomized into two groups. The first group received illumination at 3 and 4 h (20 + 55 J/cm2) after MAL-application (3/4 group). In the other group, two light fractions were performed at 3 and 5 h (20 + 55 J/cm2) after MAL-application (3/5 group). The lesion response was evaluated at 3 and 12 months posttreatment.

RESULTS: In the 3/5 group, 70.0% showed a complete response (CR) at 3 months compared to 63.6% in the other group. At 12 months, 100% showed a CR in the 3/5 group compared to 80.0% in the other group. However, most failures/recurrences were eventually due to the presence of a more aggressive BCC subtype, mostly caused by sampling error of the primary punch biopsy.

CONCLUSION: Single day protocol for MAL-PDT for sBCC is feasible and this study shows promising results.

Original language	English
Pages (from-to)	194-199
Number of pages	6
Journal	The journal of dermatological treatment
Volume	30
Issue number	2
Early online date	27 Jul 2018
DOIs	https://doi.org/10.1080/09546634.2018.1484558
Publication status	Published - Mar 2019
Externally published	Yes

Keywords

Superficial basal cell carcinoma
fractionated illumination
methyl aminolevulinate
photodynamic therapy
Photosensitizing Agents/therapeutic use
Humans
Middle Aged
Neoplasm Recurrence, Local
Male
Photochemotherapy/methods
Pilot Projects
Adult
Female
Aged
Carcinoma, Basal Cell/drug therapy
Aminolevulinic Acid/analogs & derivatives

Access to Document

10.1080/09546634.2018.1484558

nguyenFinal published version, 0.98 MB

Cite this

Nguyen, K. P., Knuiman, G. J., Blokx, W. A. M., Hoogedoorn, L., Smits, T., & Gerritsen, M. J. P. (2019). Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial. The journal of dermatological treatment, 30(2), 194-199. https://doi.org/10.1080/09546634.2018.1484558

@article{2fd2a0de57c243d3a20789e28ec0d55d,

title = "Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible?: A randomized multicenter pilot trial",

abstract = "BACKGROUND: Topical methyl aminolevulinate photodynamic therapy (MAL-PDT) is highly effective for the treatment of superficial basal cell carcinoma (sBCC). Current European treatment protocol requires two hospital visits, which is costly and unpractical. The aim of this study was to evaluate the efficacy of fractionated MAL-PDT, using two light fractions at 3 and 4 h compared to illumination at 3 and 5 h after MAL-application.METHODS: Thirty patients were randomized into two groups. The first group received illumination at 3 and 4 h (20 + 55 J/cm2) after MAL-application (3/4 group). In the other group, two light fractions were performed at 3 and 5 h (20 + 55 J/cm2) after MAL-application (3/5 group). The lesion response was evaluated at 3 and 12 months posttreatment.RESULTS: In the 3/5 group, 70.0\% showed a complete response (CR) at 3 months compared to 63.6\% in the other group. At 12 months, 100\% showed a CR in the 3/5 group compared to 80.0\% in the other group. However, most failures/recurrences were eventually due to the presence of a more aggressive BCC subtype, mostly caused by sampling error of the primary punch biopsy.CONCLUSION: Single day protocol for MAL-PDT for sBCC is feasible and this study shows promising results.",

keywords = "Superficial basal cell carcinoma, fractionated illumination, methyl aminolevulinate, photodynamic therapy, Photosensitizing Agents/therapeutic use, Humans, Middle Aged, Neoplasm Recurrence, Local, Male, Photochemotherapy/methods, Pilot Projects, Adult, Female, Aged, Carcinoma, Basal Cell/drug therapy, Aminolevulinic Acid/analogs \& derivatives",

author = "Nguyen, \{K P\} and Knuiman, \{G J\} and Blokx, \{W A M\} and L Hoogedoorn and T Smits and Gerritsen, \{M J P\}",

note = "Funding Information: This work was funded by Galderma S.A., Switzerland. Funding Information: Nguyen and Hoogedoorn received financial support from Galderma for performing clinical trials. Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 The Author(s). Published by Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2019",

month = mar,

doi = "10.1080/09546634.2018.1484558",

language = "English",

volume = "30",

pages = "194--199",

journal = "The journal of dermatological treatment",

issn = "0954-6634",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

Nguyen, KP, Knuiman, GJ, Blokx, WAM, Hoogedoorn, L, Smits, T & Gerritsen, MJP 2019, 'Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial', The journal of dermatological treatment, vol. 30, no. 2, pp. 194-199. https://doi.org/10.1080/09546634.2018.1484558

Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial. / Nguyen, K P; Knuiman, G J; Blokx, W A M et al.
In: The journal of dermatological treatment, Vol. 30, No. 2, 03.2019, p. 194-199.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible?

T2 - A randomized multicenter pilot trial

AU - Nguyen, K P

AU - Knuiman, G J

AU - Blokx, W A M

AU - Hoogedoorn, L

AU - Smits, T

AU - Gerritsen, M J P

N1 - Funding Information: This work was funded by Galderma S.A., Switzerland. Funding Information: Nguyen and Hoogedoorn received financial support from Galderma for performing clinical trials. Publisher Copyright: © 2018, © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2019/3

Y1 - 2019/3

N2 - BACKGROUND: Topical methyl aminolevulinate photodynamic therapy (MAL-PDT) is highly effective for the treatment of superficial basal cell carcinoma (sBCC). Current European treatment protocol requires two hospital visits, which is costly and unpractical. The aim of this study was to evaluate the efficacy of fractionated MAL-PDT, using two light fractions at 3 and 4 h compared to illumination at 3 and 5 h after MAL-application.METHODS: Thirty patients were randomized into two groups. The first group received illumination at 3 and 4 h (20 + 55 J/cm2) after MAL-application (3/4 group). In the other group, two light fractions were performed at 3 and 5 h (20 + 55 J/cm2) after MAL-application (3/5 group). The lesion response was evaluated at 3 and 12 months posttreatment.RESULTS: In the 3/5 group, 70.0% showed a complete response (CR) at 3 months compared to 63.6% in the other group. At 12 months, 100% showed a CR in the 3/5 group compared to 80.0% in the other group. However, most failures/recurrences were eventually due to the presence of a more aggressive BCC subtype, mostly caused by sampling error of the primary punch biopsy.CONCLUSION: Single day protocol for MAL-PDT for sBCC is feasible and this study shows promising results.

AB - BACKGROUND: Topical methyl aminolevulinate photodynamic therapy (MAL-PDT) is highly effective for the treatment of superficial basal cell carcinoma (sBCC). Current European treatment protocol requires two hospital visits, which is costly and unpractical. The aim of this study was to evaluate the efficacy of fractionated MAL-PDT, using two light fractions at 3 and 4 h compared to illumination at 3 and 5 h after MAL-application.METHODS: Thirty patients were randomized into two groups. The first group received illumination at 3 and 4 h (20 + 55 J/cm2) after MAL-application (3/4 group). In the other group, two light fractions were performed at 3 and 5 h (20 + 55 J/cm2) after MAL-application (3/5 group). The lesion response was evaluated at 3 and 12 months posttreatment.RESULTS: In the 3/5 group, 70.0% showed a complete response (CR) at 3 months compared to 63.6% in the other group. At 12 months, 100% showed a CR in the 3/5 group compared to 80.0% in the other group. However, most failures/recurrences were eventually due to the presence of a more aggressive BCC subtype, mostly caused by sampling error of the primary punch biopsy.CONCLUSION: Single day protocol for MAL-PDT for sBCC is feasible and this study shows promising results.

KW - Superficial basal cell carcinoma

KW - fractionated illumination

KW - methyl aminolevulinate

KW - photodynamic therapy

KW - Photosensitizing Agents/therapeutic use

KW - Humans

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Male

KW - Photochemotherapy/methods

KW - Pilot Projects

KW - Adult

KW - Female

KW - Aged

KW - Carcinoma, Basal Cell/drug therapy

KW - Aminolevulinic Acid/analogs & derivatives

UR - https://www.scopus.com/pages/publications/85051969921

U2 - 10.1080/09546634.2018.1484558

DO - 10.1080/09546634.2018.1484558

M3 - Article

C2 - 29862877

SN - 0954-6634

VL - 30

SP - 194

EP - 199

JO - The journal of dermatological treatment

JF - The journal of dermatological treatment

IS - 2

ER -

Nguyen KP, Knuiman GJ, Blokx WAM, Hoogedoorn L, Smits T, Gerritsen MJP. Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial. The journal of dermatological treatment. 2019 Mar;30(2):194-199. Epub 2018 Jul 27. doi: 10.1080/09546634.2018.1484558

Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this